olivLaw · European equity research
ChemoMetec A/S CHEMM.CO
Denmark · Nasdaq Copenhagen · ISIN DK0060055861 · Vertical: Listed companies from Denmark
ChemoMetec A/S develops and sells cell counting and analysis instruments used in cell and gene therapy and bioprocessing. In fiscal 2025/26 revenue rose 3% to 511.1 million DKK, and the company is focusing on its customers' automation through the new XcytoMatic platform.
At the close of 05 Nov 2026, ChemoMetec A/S (CHEMM.CO) stock was 671.50 DKK (+4.11% on the day), with market capitalisation 11.7 m DKK, P/E 0.1 on diluted EPS of 11,600.00 DKK over the last 12 months, dividend yield 1,042.59%, beta 0.88, 52-week range 236.80–782.50 DKK.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 74.6
- overbought (≥ 70)
- Bollinger (20, 2)
- 545.14 – 659.16
- above the upper band · %B 1.11 · band width 18.9%
- SMA 50 / 200
- 552.32 / 443.47
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 28.57 / 24.03
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +15.8% | +0.4% | +15.4 pp | — |
| 3 months | +61.8% | −3.3% | +65.1 pp | — |
| 6 months | +108.4% | +4.0% | +104.5 pp | — |
| Year to date | −2.3% | +8.1% | −10.4 pp | — |
| 1 year | −7.8% | +10.7% | −18.5 pp | −5.3% |
| 3 years | +103.5% | +50.1% | +53.4 pp | −0.6% |
| 5 years | −34.3% | +43.6% | −77.9 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 50 percentile of its own 2-quarter history (min 0.0, median 0.0, max 0.1; quarters with earnings only).
Fiscal years
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 495.6 m | 511.1 m |
| Revenue YoY | unavailable | +3.1% |
| Net income | 174.7 m | 201.8 m |
| Net income YoY | unavailable | +15.5% |
| Diluted EPS | 10,040.00 | 11,600.00 |
| Diluted EPS YoY | unavailable | +15.5% |
| net % | 35.3% | 39.5% |
| Free cash flow | 177.6 m | 182.0 m |
Balance sheet & financial health
Fiscal year 2026 · 30 Jun 2026
- Cash
- 290.2 m DKK
- Financial debt
- unavailable DKK
- Net debt
- unavailable DKK
- Equity
- 725.4 m DKK
- Total assets
- 860.9 m DKK
- Debt / equity
- unavailable
- Current ratio
- 4.09x
- ROE
- 28.6%
- ROA
- 23.7%
- FCF margin
- 35.6%
Financial statements (source on every figure)
Revenue and net income (DKK)
Margins
Income statement · DKK
| Line | 2025 | 2026 | Source (latest year) |
|---|---|---|---|
| Revenue | 495.6 m | 511.1 m | esef· 15 Oct 2026verified |
| Gross profit | 465.5 m | 486.0 m | esef· 15 Oct 2026verified |
| Operating income | 236.5 m | 251.0 m | esef· 15 Oct 2026verified |
| Depreciation & amortisation | 21.5 m | 30.3 m | esef· 15 Oct 2026verified |
| EBITDA | 258.0 m ≈ | 281.3 m ≈ | esef· 15 Oct 2026derived |
| Interest expense | 17.4 m | 392.0 k | esef· 15 Oct 2026verified |
| Pre-tax income | 225.0 m | 258.2 m | esef· 15 Oct 2026verified |
| Income tax | 50.3 m | 56.3 m | esef· 15 Oct 2026verified |
| Net income | 174.7 m | 201.8 m | esef· 15 Oct 2026verified |
| Diluted EPS | 10,040.00 | 11,600.00 | esef· 15 Oct 2026verified |
| Dividend per share | 4,000.00 | 7,000.98 | esef· 15 Oct 2026derived |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · DKK
| Line | 2025 | 2026 | Source (latest year) |
|---|---|---|---|
| Cash | 341.8 m | 290.2 m | esef· 15 Oct 2026verified |
| Inventories | 120.8 m | 126.2 m | esef· 15 Oct 2026verified |
| Current assets | 554.6 m | 524.8 m | esef· 15 Oct 2026verified |
| Property, plant & equipment, net | 115.6 m | 126.6 m | esef· 15 Oct 2026verified |
| Goodwill | 7.4 m | 7.4 m | esef· 15 Oct 2026verified |
| Intangibles (excl. goodwill) | 153.0 m | 208.2 m | esef· 15 Oct 2026verified |
| Total assets | 839.5 m | 860.9 m | esef· 15 Oct 2026verified |
| Current liabilities | 143.7 m | 128.2 m | esef· 15 Oct 2026verified |
| Total liabilities | 151.4 m | 135.5 m | esef· 15 Oct 2026verified |
| Equity | 688.1 m | 725.4 m | esef· 15 Oct 2026verified |
| Shares outstanding at year end | 17.4 k | 17.4 k | esef· 15 Oct 2026derived |
Cash flow · DKK
| Line | 2025 | 2026 | Source (latest year) |
|---|---|---|---|
| Operating cash flow | 207.4 m | 210.4 m | esef· 15 Oct 2026verified |
| Capex | 29.9 m | 28.3 m | esef· 15 Oct 2026verified |
| Free cash flow | 177.6 m ≈ | 182.0 m ≈ | esef· 15 Oct 2026derived |
| Investing cash flow | -85.5 m | -99.8 m | esef· 15 Oct 2026verified |
| Financing cash flow | -75.0 m | -161.6 m | esef· 15 Oct 2026verified |
| Dividends paid | 69.6 m | 121.8 m | esef· 15 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 52.1% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 11.7 m DKK
Key indicators
Coverage and freshness
Score by group
52% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 52.1% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 39.5% | 89 (vs peers) | 12% |
| FCF conversion · Quality | 90.2% | 86 (on a fixed band) | 12% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 640.3x | 100 (on a fixed band) | 12% |
| Current ratio · Balance sheet | 4.1x | 100 (on a fixed band) | 8% |
| P/E (TTM) · Valuation | 0.1x | 100 (vs peers) | 20% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 1,558.1% | 100 (on a fixed band) | 16% |
| Shareholder yield (distributions) · Returns | 1,042.6% | 100 (on a fixed band) | 12% |
| Payout ratio (FCF) · Returns | 66.9% | 76 (on a fixed band) | 8% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet100/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality88/100 · 2/3 factors with a value
- Returns90/100 · 2/2 factors with a value
- Valuation100/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
CHEMOMETEC A/S (CHEMM.CO). Latest full fiscal year: 2026; data up to 2026-06-30.
Figures computed from the financial statements: revenue 511.1 m DKK in 2026; YoY growth 3.1%; net margin 39.5%; ROE 28.6%.
The estimated value range is 106,274.54–179,969.96 DKK per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 116,039.47 DKK, the price of 671.50 DKK leaves a potential of 17,180.6% (value / price − 1) and a margin of safety of 99.4% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 52.1% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 39.5%
- FCF conversion: 90.2%
- Interest coverage: 640.3x
- Current ratio: 4.1x
- P/E (TTM): 0.1x
- FCF yield: 1,558.1%
- Shareholder yield (distributions): 1,042.6%
- Payout ratio (FCF): 66.9%
- The price is below the estimated value range
What contradicts it
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): ROIC, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA.
Versus the vertical median
Listed companies from Denmark · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| DEMANT.CODemant A | 79.7 bn | 51.6 | 15.0% | 6.7% | +2.5% | +72% / +30% |
| PNDORA.COPandora A | 68.8 bn | 13.2 | 133.4% | 16.1% | unavailable | +16% / −3% |
| NEWCAP.CONewcap Holding A | 65.3 bn | 13,125.0 | 29.1% | 41.6% | −99.9% | +121% / +62% |
| ISS.COIss A | 50.8 bn | 19.8 | 27.7% | 3.1% | +1.1% | +43% / +158% |
| BAVA.COBavarian Nordic A | 19.2 bn | 13.9 | 10.9% | 22.0% | unavailable | +33% / +47% |
| GN.COGn Store Nord A | 18.1 bn | 27.7 | 6.3% | 6.8% | unavailable | +20% / −23% |
| NETC.CONetcompany Group A | 16.8 bn | 66.2 | 7.2% | 3.3% | unavailable | +11% / +64% |
| BIOMAR.COBiomar Group A | 12.1 bn | 16.9 | 28.3% | 4.3% | −0.5% | unavailable / unavailable |
| JDAN.COJeudan A | 11.1 bn | 11.1 | 7.7% | 57.1% | unavailable | +2% / −7% |
| DFDS.CODfds A | 8.7 bn | — | -0.2% | -0.1% | +1.9% | +73% / −25% |
| GUBRA.COGubra A | 4.8 bn | 2.9 | 149.6% | 64.1% | +892.2% | −40% / +157% |
| MATAS.COMatas A | 3.1 bn | 12.9 | 6.6% | 2.8% | +4.7% | −31% / −21% |
| CBRAIN.COCbrain A | 2.4 bn | 54.7 | 13.8% | 17.2% | −6.2% | −21% / −52% |
| BO.COBang & Olufsen A | 1.7 bn | — | -10.0% | -4.3% | −3.3% | −24% / +12% |
| COLUM.COColumbus A | 1.2 bn | 84.0 | 2.0% | 0.9% | unavailable | −5% / +30% |
| NNIT.CONnit A | 1.0 bn | — | -3.0% | -1.3% | −3.4% | −16% / −54% |
| NORTHM.CONorth Media A | 873.1 m | 13.2 | 5.5% | 5.1% | −0.4% | +11% / −16% |
| FFARMS.COFirstfarms A | 789.8 m | — | -2.3% | -5.4% | −16.5% | −9% / −1% |
| HUSCO.COHusCompagniet A | 507.2 m | — | -1.3% | -0.9% | +28.7% | −41% / −46% |
| BIOPOR.COBioporto A | 456.2 m | — | -117.6% | -203.8% | +11.2% | −8% / −53% |
| GABR.COGabriel Holding A | 429.4 m | 57.5 | 2.8% | 1.4% | +6.7% | −10% / −29% |
| GREENM.COGreenMobility A | 392.5 m | 11.9 | 74.3% | 21.5% | +20.0% | −19% / +91% |
| EGNETY.COEgnsinvest Ejendomme Tyskland A | 320.0 m | 13.0 | 4.0% | 40.9% | −2.6% | −21% / +11% |
| PFINV.COPapirfabrikken Invest A | 300.9 m | 13.5 | 5.4% | 29.7% | +0.9% | −3% / +36% |
| CEMAT.COCemat A | 213.9 m | 3.5 | 28.7% | 37.5% | +318.0% | −9% / +3% |
1- and 3-year price returns: for CHEMM.CO from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (DKK)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 391.42 Total return 769% · Per year 769% | 692.47 Total return 1,078% · Per year 1,078% | 1,043.69 Total return 1,352% · Per year 1,352% |
| 3 years | 369.45 Total return 2,317% · Per year 189% | 736.42 Total return 3,337% · Per year 225% | 1,220.17 Total return 4,295% · Per year 253% |
| 5 years | 348.72 Total return 3,779% · Per year 108% | 783.16 Total return 5,739% · Per year 126% | 1,426.49 Total return 7,737% · Per year 139% |
- Exit P/E± 184.10
- Net margin± 128.87
- Annual revenue growth± 107.20
- Annual dilution± 10.83
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
ChemoMetec A/S develops and sells cell counting and analysis instruments used in cell and gene therapy and bioprocessing. In fiscal 2025/26 revenue rose 3% to 511.1 million DKK, and the company is focusing on its customers' automation through the new XcytoMatic platform.
SWOT
Strengths
- Strong position in cell and gene therapy, where many important customers are already the company's customers.
- Product range covering both semi-automated instruments and fully automated systems.
- Growth in new instrument sales, supported by the launch of the XcytoMatic platform.
Weaknesses
- Dependence on production processes and proprietary technology, which require investment and validation time at customers.
- Reagents are currently produced by a third party, which limits direct control over supply.
- Intense validation and support activity has increased the workload of sales and service teams.
Opportunities
- The withdrawal of some competing products in bioprocessing could open new market share.
- Demand for automation and integration in therapy production could support sales of XcytoMatic systems.
- Partnerships with other automation suppliers may open additional distribution channels.
Threats
- Reduced funding for early-stage biotech companies may slow purchases.
- Established competitors in bioprocessing may respond with new products or aggressive pricing.
- High costs of therapies may lead customers to postpone investments.
Risks
- Dependence on external reagent productionmedium
Reagent production is outsourced, so problems at the supplier could affect deliveries.
- Dependence on the cell therapy markethigh
A decline in investment in cell and gene therapy could reduce demand for the company's instruments.
- Slow pace of customer transformationmedium
Customers' automation projects are large and long-running, which could delay revenue.
- Competition in bioprocessingmedium
If established competitors keep their positions, the company could gain less from their withdrawals than it expects.
Investment thesis
What would need to be true (bull case)
- Rapid growth in XcytoMatic instrument sales shows the platform is finding new buyers.
- A position among major customers in cell therapy provides a stable base for extending automation.
- The withdrawal of some bioprocessing competitors could open a substantial niche for the company.
What would break the thesis
- Revenue growth remained modest, only slightly above the inflation rate in the recent period.
- If biotech funding does not recover, demand for instruments could remain weak.
- The transition from older products and new validations may delay the financial effects of the new platform.
What to watch
- Quarterly results of the XcytoMatic segmentQ1 2027
- Progress of strategic partnerships with other suppliers2027
- Guidance for fiscal 2026/27 in the next annual reportnext annual report
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
ChemoMetec designs cell analysis instruments, consumables (cassettes, reagents, test kits) and software, mainly produced at Allerød, Denmark. Sales are made through its own organisations in the US and Europe and through distributors in Asia. The company states that some of its products enter customers' value chains as critical elements, which makes production quality a priority.
The US sales organisation was reorganised into four regions with their own managers, and a new office is opening in San Francisco. The company says almost all of the top 50 companies in cell and gene therapy are its customers, which strengthens its position in this market.
Segments
Cell and gene therapy
The main segment, where customers are pharma and biotech companies, universities and hospitals. The company sees automation of therapy production as a growing strategic direction.
Bioprocessing
A large and growing market for which the XM40 instrument is designed, since it can process many samples at once. The company says some established competitors are withdrawing products, which opens opportunities.
Market context
The cell and gene therapy market was affected in recent years by lower availability of capital, especially for companies in early stages, but the company observes signs of stabilisation. Growth is expected from approvals of new therapies and from more efficient production. In bioprocessing, demand for biologics and biosimilars supports a market considered large and expanding.
An adjacent area is the food and beverage industry, where cell analysis is used for quality control of animal semen, eggs and milk. The company considers these segments complementary to its core research and production activity.
Trends
- Automation of therapy productiontailwind
Customers are seeking to reduce production costs, which increases demand for integrated and automated solutions. This favours the XcytoMatic platform but also requires more skills and cooperation between departments.
- Uncertainty in customer marketsheadwind
If funding for early-stage biotech companies remains low, demand for research instruments could decline.
- Partnerships and wider distributionmixed
Collaboration with other automation suppliers opens new distribution channels, but integration processes are slower and more complex than selling standalone instruments.
Competitive position
The company notes it is one of the few suppliers able to integrate cell counting into larger automation solutions. In bioprocessing, however, established competitors have for years dominated the market for analysis instruments.
- Established bioprocessing analysis instrument suppliers
The company mentions that some of these suppliers have planned to end sales of several products, creating an opportunity, without being named in the source.
- Suppliers of integrated automation solutions
Competition comes from suppliers offering complete automation systems, which ChemoMetec complements through partnerships.
- Test kit and reagent manufacturers
The company has its reagents produced by a subcontractor, so competition in this area also affects its supply chain.
- Other cell counter suppliers
Several suppliers compete in the general cell counting market, and the company differentiates through its fluorescence technology and AI.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202615 Oct 2026
- Annual report 202504 Mar 2026
Sources
- [1] Annual report, fiscal year ended 2026-06-30 (ESEF) · SEC / ChemoMetec A/S · 30 Jun 2026
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.